Skye Bioscience, Inc. SKYE 深 沪
等待开盘 04-02 09:30:00 美东时间
0.6649
+0.050
+8.18%
华盛通- 最 高0.7223
- 今 开0.66
- 成交量 56.11万股
- 最 低 0.6401
- 昨 收 0.6146
- 总市值 2219.35万
- 52周最高 5.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.5655
- 委 比 0.99%
- 总股本 3337.88万
- 历史最高 17.6473
- 量 比 2.26
- 振 幅 13.37%
- 历史最低 0.5655
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Skye Bioscience shares are trading lower after the company reported a Q4 EPS miss.
Skye Bioscience shares are trading lower after the company reported a Q4 EPS mi...
03-12 00:12
Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 117.65% and reporting a rise in revenue.
03-11 17:57
Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate
Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 21.21 percent. This is a 50 percent decrease over losses of $(0.24) per share from
03-11 04:02
Earnings Scheduled For March 10, 2026
Companies Reporting Before The Bell • Ultralife (NASDAQ:ULBI) is likely to repo...
03-10 19:11
A Peek at Skye Bioscience's Future Earnings
Skye Bioscience (NASDAQ:SKYE) is set to give its latest quarterly earnings repo...
03-10 01:02
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Icecure Medical (NASDAQ:ICCM) shares moved upwards by 17.7% to $0.68 d...
03-02 20:05
Skye Bioscience Presents Nimacimab-Tirzepatide Data At Keystone Obesity Therapeutics Conference
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled
01-29 20:14
Skye Bioscience Issues 2026 Corporate Outlook Outlining Planned Clinical, Manufacturing, And Corporate Milestones To Advance Nimacimab, Skye's Peripherally Restricted CB1-Inhibiting Antibody
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026.CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety
01-12 20:59
Skye Bioscience Announced Non-Exclusive License Agreement For Halozyme Therapeutics' Enhanze Drug Delivery Technology For The Development And Potential Commercialization Of A Subcutaneous Formulation Of Nimacimab For Obesity
Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE
01-05 20:16
